Uniqure NV

QURE · NASDAQ

$22.72+$0.515 (+2.32%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $22.20

QURE analyst rating

BuyConsensus of 13 analysts over the last 12 months. 77% rate it a buy.

Strong buy0
Buy10
Hold3
Underperform0
Sell0

12-month price target · 13 analysts

Average $66.58 (+193.1% upside)

Low: $31.31
Now: $22.72
High: $99.75

Upgrades and downgrades

The latest rating actions, newest first

QURE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 15, 2026	Initiates	Buy	$27.00 → $48.00	69%
Barclays	Oct 5, 2026	Downgrade	Overweight → Equal-Weight	$60.00 → $28.00	45%
RBC Capital	Oct 2, 2026	Maintains	Outperform	$65.00 → $48.00	44%
Goldman Sachs	Sep 30, 2026	Maintains	Neutral	$46.00 → $31.00	47%
William Blair	Sep 2, 2026	Initiates	Outperform	—	13%
Wells Fargo	Jul 30, 2026	Maintains	Overweight	$60.00 → $75.00	32%
Wolfe Research	Jul 30, 2026	Upgrade	Peer Perform → Outperform	$65.00	60%
Barclays	Jul 30, 2026	Maintains	Overweight	$65.00 → $60.00	45%
HC Wainwright & Co.	Jun 29, 2026	Maintains	Buy	$50.00 → $80.00	33%
Mizuho	Jun 25, 2026	Maintains	Outperform	$35.00 → $68.00	46%

The case for and against

Updated Oct 14, 2026

Bull case

uniQure is supported by a compelling regulatory reset in Huntington’s disease, as the FDA now appears willing to accept the 3-year Phase I/II data for a 3Q26 BLA and potentially review it under an accelerated-approval framework without sham surgery control. The clinical package is still imperfect, but the totality of evidence points to meaningful slowing of disease progression across multiple endpoints and time points, while the company’s plan for a ~200-patient confirmatory study reduces ethical and operational friction. Fundamentally, the investment case is reinforced by a durable gene-therapy platform, first/best-in-class Hemophilia B attributes, early mTLE signals, and a large initial HD opportunity of about 6,000 eligible patients on day one.

Bear case

uniQure is burdened by a high-risk, clinical-stage profile in which value depends heavily on unproven programs such as AMT-130, AMT-260, AMT-162, and AMT-191, while commercialization risk for HEMGENIX remains elevated. Regulatory uncertainty, intellectual property risk, trial execution issues across HD, SOD1, TLE, and Fabry, and the possibility of a safety signal or failure to show sustained efficacy all threaten the pipeline’s conversion into durable cash flows. Even with a modeled total firm value of approximately $5.5 billion and a 12% discount rate, the path to monetization is pushed into the 2030s, leaving the stock exposed to dilution, reimbursement pressure, and competition from PFE, IONS, and WVE.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.